Wegovy HD hits the U.S.

Novo Nordisk just put a stronger version of Wegovy into U.S. pharmacies: Wegovy HD is a 7.2 milligram shot, and the company says it is now available nationwide through more than 70,000 pharmacies, NovoCare Pharmacy, and some telehealth providers. (prnewswire.com) This is the same drug ingredient, semaglutide, just pushed to a higher weekly dose after patients have already tolerated the standard 2.4 milligram version for at least four weeks. (empr.com) Wegovy belongs to a class of obesity drugs that copy a gut hormone signal telling the brain you have eaten enough, which is why people often describe them as turning down the food noise rather than acting like old stimulant diet pills. (nejm.org) Novo Nordisk got United States Food and Drug Administration approval for Wegovy HD on March 19, 2026, and the agency said the decision came 54 days after filing under its Commissioner’s National Priority Voucher pilot program. (fda.gov) The selling point is simple: more dose, more weight loss. In the STEP UP phase 3b trial, Novo Nordisk said adults with obesity lost about 20.7% of body weight on average at 72 weeks with Wegovy HD if everyone stayed on treatment, versus 17.5% with the 2.4 milligram dose. (novonordisk.com) That turns Wegovy HD into a defensive move as much as a product launch, because Eli Lilly’s Zepbound has been winning attention with stronger weight-loss data in the same market. (zepbound.lilly.com) Novo is not just fighting on efficacy anymore. Bloomberg reported the company set Wegovy HD at $399 a month for cash-pay patients, about 40% below what Lilly charges cash-pay patients for Zepbound’s top three doses. (bloomberg.com) Lilly still has a cheaper front door for some self-pay patients: its Zepbound savings page advertises prices starting at $299 for a one-month prescription, but that “starting at” language does not apply evenly across every dose and device. (lilly.com) Novo has also been cutting prices across the semaglutide franchise. Its U.S. news archive shows the company announced “significant” list-price reductions for Wegovy, Ozempic, and Rybelsus on February 24, 2026, then added a multi-month Wegovy subscription program on March 31. (novonordisk-us.com) So the U.S. obesity-drug fight now looks less like one blockbuster medicine facing another and more like two companies building full shelves: higher-dose shots, lower cash prices, subscription offers, telehealth channels, and pills. Wegovy HD matters because it gives Novo Nordisk one more lever in that price-and-access war, not just one more pen strength. (biopharmadive.com)